EZH2 and hepatocellular carcinoma: The authors proposed that EZH2 suppresses PD-L1 expression via epigenetic modification, by upregulating H3K27me3 levels at the CD274 (which encodes PD-L1) and IRF1 gene in hepatoma cells, highlighting the critical role of EZH2 in reshaping the tumour immune microenvironment [38].